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Summary An immunocytochemical method was used to test the reactivity of the anti-P-glycoprotein anti-
bodies, C219, MRK 16, JSB-1 and 265/F4 against multidrug resistant (MDR) variants derived from the
human small cell lung carcinoma line, NCI-H69, the mouse fibrosarcoma line, RIF- 1 and the mouse
mammary tumour cell line, EMT6. C219 produced positive staining in MDR variants of both human and
mouse tumour cell lines. MRK 16 and JSB-1 however recognised P-glycoprotein only in the human MDR cell
lines and not in the mouse MDR cells. 265/F4 appeared the most selective of the monoclonal antibodies used,
producing positive staining of MDR variants derived from the RIF-1 line, but not of MDR variants derived
from the EMT6 line. Total RNA was prepared from the mouse cell lines and, following reverse transcription,
cDNA sequences were amplified by the polymerase chain reaction with primers specific for either the murine
mdrla or the mdrlb genes. From this it was possible to show that only the mdrla gene is overexpressed in the
resistant EMT6 lines that do not stain with 265/F4 whereas both mdrla and mdrlb are overexpressed in
the positively staining resistant fibrosarcoma line, RIF/1.0. Low level expression of mdrlb was detected in the
sensitive parent RIF-1 cells and increasing levels ofexpression correlated with increasing resistance in the lines,
RIF/0.1, 0.2, 0.4 and 1.0. Expression of mdrla was found only in the more resistant fibrosarcoma cell lines. It
seems that 265/F4 recognises only the mdrlb P-glycoprotein. Western blotting confirmed that this antibody
detects a 170 kDa protein only in membranes derived from the resistant fibrosarcoma cells. 265/F4 may thus
be used to distinguish between the murine P-glycoprotein isoforms so revealing differences between tumour cell
lines in cellular localisation and in the time of appearance of mdrla and mdrlb P-glycoprotein following drug
exposure.
Inherent and/or acquired patterns of cross-resistance to
groups of cytotoxic drugs have proved major obstacles to the
successful chemotherapy of cancer. One major mechanism of
multidrug resistance involves the overexpression of P-glyco-
protein on the cell surface (Juranka et al., 1989). In an
attempt to evaluate the importance of this putative drug
efflux pump, a variety of monoclonal antibodies (MAbs)
directed against the protein have been used on both normal
and tumour tissue and on multidrug resistant (MDR) cell
lines. These MAbs include C219, MRK 16 and JSB-1 all of
which have been found appropriate for use on clinical mate-
rial (Grogan et al., 1990). Differences in staining patterns
have however been observed with these antibodies (Van de
Valk et al., 1990). Although the basic P-glycoprotein struc-
ture is conserved across species, there are still structural
differences between the P-glycoproteins of different species
and of different tissues within species (Juranka et al., 1989).
In the mouse, there are three different genes coding for
P-glycoproteins, alternatively known as mdrla, mdrlb and
mdr2 (Hsu et al., 1989) or as mdr3, mdrl and mdr2 (Croop et
al., 1989). In humans there are only two P-glycoprotein-
encoding genes, known as mdrl and mdr2 or as mdrl and
mdr3 (Schinkel et al., 1991). The selectivity of a particular
antibody will thus depend on whether the epitope recognised
is easily accessible, is in a region of the protein which is
highly conserved between isoforms and whether it is unique
to a specific P-glycoprotein.
Epitope mapping has helped in identifying more precisely
the relevant sequences. C219 which was raised against solu-
bilised membranes from both Chinese hamster ovary and
human leukaemic MDR cells (Kartner et al., 1985), is known
to detect a cytoplasmic sequence six residues away from the
consensus sequence of the B site of the proposed ATP-
binding domain. This is a highly conserved amino acid
sequence found in all P-glycoprotein isoforms characterised
(Georges et al., 1990). C219 therefore provides a fairly
general probe for P-glycoproteins. It may however recognise
sequences present on other proteins unrelated to P-glyco-
protein (Thiebaut et al., 1989). MRK 16, originally raised
against intact adriamycin-resistant human myelogenous leu-
kaemic cells (Hamada & Tsuruo, 1986), recognises an exter-
nal epitope on cells expressing the human mdrl gene but
probably does not recognise P-glycoprotein from any other
species. Its epitope encompasses at least two of six predicted
extracellular peptide loops and so it has been suggested that
the sequences involved which are separated by about 625
amino acids in the linear structure must be spatially situated
in close proximity in the native protein (Georges et al., 1991).
There are also reports that sialation may mask detection of
the epitope (Cumber et al., 1990). Less is known about
JSB-1. This antibody which was originally raised against a
colchicine-selected mutant of a Chinese hamster ovary
(CHO) cell line (Scheper et al., 1988) is thought to bind a
cytoplasmic domain of the protein. Yet there are reports
from studies on human tissues that staining with JSB-1 can
occur in the absence of detectable mdrl RNA expression
(Van der Valk et al., 1990). A MAb, 265/F4, which was
originally raised against resistant Chinese hamster ovary
whole cells (Lathan et al., 1985) has also been used to stain
human tissues. It detects a 170 kDa protein in CHO resistant
cell membranes and also gives positive staining with MDR
variants of mouse sarcoma and leukaemic cell lines (Volm et
al., 1988a and b, 1989). It has produced positive staining on
resistant forms of human epidermoid lung cancer grown as
xenographs (Volm et al., 1988a) and has stained cells in nine
of 21 cases of human renal carcinoma (Bak et al., 1990). In
this study, essentially identical results were obtained with
C219 used to stain parallel slides. However 265/F4 did not
detect a 170 kDa protein in Western blots of cell membrane
preparations from human resistant breast carcinoma cells
(Lathan et al., 1985).
The study described in this paper was undertaken to estab-
lish the appropriateness of C219, MRK 16, JSB-1 and 265/
F4 for detecting P-glycoprotein in certain of our drug resis-
tant human and mouse tumour cell lines. As a result of the
different staining patterns obtained, it became apparent that
different P-glycoprotein isoforms were being expressed in the
resistant mouse cells derived from different tumours. Prelim-
inary results of some of this work have been reported pre-
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viously in abstract form (Barrand et al., 1990, 1991; Barrand
& Twentyman, 1991).
Materials and methods
Cell lines
The human cell lines studied were the human small cell lung
carcinoma line NC1-H69P and its resistant variants, H69/
LX4 and LX20 selected in adriamycin and H69/VR2 selected
in vincristine. It has been shown previously that expression of
human mdrl RNA is present in the resistant small cell lung
lines (Reeve et al., 1989a). These resistant lines were derived
as described previously (Twentyman et al., 1986) and were
maintained in RPMI 1640 medium supplemented with 10%
foetal calf serum, penicillin and streptomycin (all Gibco
Europe Ltd). The two mouse cell lines investigated were
EMT6 originating from a mouse alveolar tumour nodule
transplanted into a mammary fat pad (Rockwell et al., 1972)
and RIF-1 obtained from a fibrosarcoma (Twentyman et al.,
1980). Cells were maintained in Eagle's minimum essential
medium supplemented with either 20% new born calf serum
or 10% foetal calf serum together with glutamine, penicillin
and streptomycin. Resistant variants of EMT6 cells were
derived by continuous growth of the parent (EMT6P) cell
line in increasing concentrations of either adriamycin
(ADM), vincristine (VCR) or colchicine (COL) and were
maintained in the presence of the selecting drug at 0.2 Lg
ml-' (CR0.2), 1 gIgml' (ARL.0, VR1.0) or 2figmlP'
(CR2.0) (Reeve et al., 1989b). Resistant variants of RIF cells
were derived by adriamycin selection and were maintained in
the presence of adriamycin at 0.1 ig ml-' (RIF0.1), 0.2,tg
ml-' (RIF 0.2), 0.4 igml1' (RIF 0.4) or 1.0gLgml' (RIF
1.0). Previous studies involving Northern blot analysis with
probe pcDRI.3 for the mouse ADRl1 gene coding for P-
glycoprotein revealed the presence of increased levels of mdr
RNA of a size similar to that of human mdrl mRNA (Reeve
et al., 1989a) in the resistant variants of both EMT6 and RIF
cell lines (Twentyman et al., 1990b; Dr P. Rabbitts, personal
communication). Values for the resistance of all these lines to
adriamycin compared to their parent lines are shown in
Table I.
Immunohistochemical detection ofP-glycoprotein
An alkaline phosphatase-antialkaline phosphatase (APAAP)
method was used both for histochemical localisation and for
whole cell ELISA assay. Cells harvested by trypsinisation
followed by washing in phosphate buffered saline (PBS) were
made into cytospins and air dried or absorbed to 96-well
plates at 5 x I04 and 105 cells per well by overnight incuba-
Table I Description of human and mouse resistant tumour cell
lines
Maintenance dose of
Resistant cell Selecting selecting agent Resistance to
lines agent (jigml/-') ADM*
Human
H69/LX4 ADM 0.4 85 a
H69/LX20 ADM 2.0 200 b
H69/VR2 VCR 2.0 450 b
Mouse
EMT6/CR0.2 COL 0.2 17 c
EMT6/VR1.0 VCR 1.0 35 c
EMT6/ARI.0 ADM 1.0 69 c
EMT6/CR2.0 COL 2.0 190 c
RIF/0.1 ADM 0.1 10 d
RIF/0.2 ADM 0.2 30 d
RIF/0.4 ADM 0.4 80 d
RIF/1.0 ADM 1.0 180 d
*Resistance measured as ID50 for resistant line/ID50 for sensitive
parent line. (a) Twentyman et al., 1986; (b) Twentyman, unpublished;
(c) Twentyman et al., 1990a; (d) Barrand et al., 1991.
tion at 37°C. The staining protocol was essentially the same
for cytospins or ELISA plates except that cells on the cytos-
pins were fixed in acetone at room temperature for 10min
prior to staining whilst cells in the ELISA wells were not.
After a wash in Tris-buffered saline (TBS), cells were sub-
jected to three 1 h incubations at room temperature. The first
incubation was with MRK16 (gift from Prof Tsuruo) at
30gigml1', JSB-1 (Sanbio) at 1:20 dilution of ascites, C219
(Centocor) at 10.gmm1', 265/F4 (kindly donated by Prof
McGuire) at 10l gmlgl or 0.14% mouse serum as blank.
The second incubation was with rabbit antimouse immuno-
globulins (Z259 from Dakopatts) diluted 1 in 25, and the
third with the antialkaline phosphatase-alkaline phosphatase
conjugate (D263 from Dakopatts) diluted 1 in 50. Each
antibody was diluted in TBS containing 1% rabbit serum.
The second and third incubation steps, this time only of
30 min duration, were repeated once. Following washing in
TBS, cytospins were exposed to a substrate mix containing
0.2 mgml1' naphthol-AS-MX-phosphate, 1 mg ml' Fast
Red TR salt, 2 mM levamisole and 2% N-N-dimethylform-
amide in 0.1 M Tris buffer at pH 8.2 which produces an
insoluble red precipitate. Cells in the ELISA wells were
exposed to I mgml1' Sigma 104 phosphatase substrate,
1 mM MgCl2 and 2 mM levamisole in 0.2 M AMP (2-amino-2-
methyl-l-propanol) buffer at pH 9.8, which gives rise to a
soluble yellow product, the absorbance of which may be
measured at 405 nm. Cytospins were counterstained in hae-
matoxylin and mounted in glycerol.
Protein separation andimmunoblotting
Cells were washed and scraped from their growing surface
into PBS containing a, PMSF at 100 .tg ml1' or b, apop-
rotein at 2 igml-', leupeptin at 5 jigml-' and pepstatin at
0.08 gLgml-'. Following disruption by sonication, nuclei were
removed from the homogenates by centrifugation at 400g for
10 min at 4°C and cell membranes separated from the resul-
tant supernatant by centrifugation at 60,000g for 40 min at
4°C. The membranes were solubilised in 0.1% SDS and the
protein content determined using a BCA protein assay kit
(Pierce (UK) Ltd, Cambridge, UK). Proteins were resolved
by SDS electrophoresis in 7.5% polyacrylamide, electroblot-
ted onto nitrocellulose at 4°C for 3-4 h at a constant current
of 0.5A using a transfer buffer containing 0.0125 M Tris,
0.2 M glycine (at pH 8.5) and 20% methanol. They were then
subjected to sequential overnight incubations at 4°C, firstly
with blocking buffer (NGA) containing 5 mM EDTA, 0.25%
gelatin, 0.01 M NaN3, 0.15M NaCI, 0.05 M Tris at pH 7.4
and 0.05% Nonidet P40, secondly with C219 at 25 ngml'
or with 265/F4 at 25 ngml` diluted in NGA buffer and
finally with '251I-labelled rabbit antimouse Ig diluted 1:1000 in
NGA buffer before autoradiography.
RNA preparation, electrophoresis and Northern blotting
Total cellular RNA was prepared from cells lysed in guani-
dine chloride by ethanol precipitation and phenol/chloroform
extraction of proteins as described previously (Reeve et al.,
1989a). Fifteen to thirty fig of total cellular RNA, denatured
by glyoxalation, were separated by electrophoresis through
1.4% agarose in 10 mM sodium phosphate buffer at pH 7.0
and transferred to nitrocellulose filters by Northern blotting.
First strand cDNA synthesis andamplification by PCR
cDNA sequences were synthesised from 1-5gLg of total cellu-
lar RNA in the presence of 10 mM dithiothreitol, 6 mM
MgC12, 40 mM KCI, 200giM of each deoxynucleoside triphos-
phate, 2.5 gig of DNAase/RNAase free bovine serum albumin
and 50 mM Tris buffer at pH 8.3 with 0.5 gig of random
hexamer, pd(N)6 as primer in a total volume of 25gil. After
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units of super reverse transcriptase were added to initiate
DNA synthesis and the reaction mixture incubated at 42'C
for 1-2 h. Five to ten tlI of this mixture was then used for
amplification of specific DNA sequences in the presence of
2 mm MgCl2, 50 mM KCI, 200 gM of each deoxynucleoside
triphosphate, 5pg of DNAase/RNAase free bovine serum
albumin and 20 mM Tris buffer at pH 8.3 together with
50 pmoles of each primer in a total volume of 50 tlI. The
reaction was initiated by addition of 2 Units of Taq poly-
merase (Cetus) and amplification proceeded through 30
cycles of 95'C for 1 min, 55°C for 2 min and 72'C for 2 min.
The sequence of the reverse primer (CGAGCCTGGTGGTC-
AGT) was common to all mouse mdr genes, representing
bases 1930-1913 in mdrla otherwise termed mdr3 (Hsu et
al., 1989, 1990) and 2449-2432 in mdrlb otherwise termed
mdrl (Gros et al., 1986b). The sequences of the forward
primers were specific either to the mdrla gene (AGCATC-
TGTGGACCACATG) or to the mdrlb gene (TGCATACA-
ACCAGTGTTTG) representing bases 1485-1503 in mdrla
and 2161-2179 in mdrlb. The amplification products were
separated by electrophoresis in 2% agarose in a buffer con-
taining 20 mM sodium acetate, 40 mM Tris and 0.2 mM
EDTA at pH 8.3 and visualised by u.v. in the presence of
ethidium bromide. For further identification of the sequences,
the amplified DNA products were blotted onto nylon filters.
Preparation ofradiolabelledprobes andhybridisation
The pcDRI.3 probe for the mouse ADRl gene coding for
P-glycoprotein (Gros et al., 1986a) was generously provided
by Dr James M. Croop (Centre for Cancer Research, Massa-
chusetts Institute of Technology, USA). This probe was
oligolabelled with 32P-CTP using Klenow fragment DNA
polymerase and separated from unbound label by centrifuga-
tion through Sephadex G-50. Following prehybridisation for
1 h at 65°C with the hybridisation mixture containing 1%
SDS, 6 x SSC, 0.5% salmon sperm DNA, filters were expos-
ed overnight at 65'C to the labelled probe diluted in the
hybridisation mixture and subsequently washed several times
at 65'C in a mixture containing 0.1 x SSC and 0.1% SDS
before being subjected to autoradiography.
Results
The monoclonal antibodies MRK16, JSB-1 and C219 pro-
duced cell edge staining in 60-70% of cells of the human
MDR cell lines, H69/LX4, LX20 and VR2 but not in the
sensitive parent cell line, H69/P (Table II). The antibody,
265/F4 did not stain any of the parent or resistant human
cell lines. By contrast, MRK16 and JSB-1 did not detect
P-glycoprotein in any of the resistant mouse cell lines. C219
however still produced strong cytoplasmic and edge staining
in the resistant variants, but not the sensitive parent cells of
both the EMT6 (Figures la and lb) and the RIF lines
(Figure ic). With 265/F4, no staining was visible in the
resistant (Figure Id) or parent EMT6 cells, but strong cell
edge and cytoplasmic staining was evident in the resistant
cells of the RIF line (Figure le). In each resistant cell line,
staining with both C219 and 265/F4 was heterogeneous with-
in the cell population, 60-70% of cells being positive. Stain-
ing in the less resistant lines, RIF/0.1 and RIF/0.2 (Figure 1f)
appeared not to be at the cell edge, but predominantly in
patches in the cytoplasm. Subcellular fractionation studies
are now being undertaken to determine whether this appar-
ent intracellular location of P-glycoprotein is genuine. If so it
raises interesting possibilities with regard to the function of
the protein in normal tissues and to the effect of the protein
on cytotoxic drug distribution in resistant cells.
To obtain more quantitative analysis of the above
immunohistochemical data, we performed whole cell ELISA
assays on the mouse cell lines. These showed staining inten-
sity with both C219 and with 265/F4 to increase in parallel
with increasing resistance in the RIF cell lines (Table III).
C219 also produced strong staining with the resistant EMT6
cells, but there was not such a close correlation between
resistance and absorbance in these EMT6 lines. Differences in
cell size and therefore in membrane surface areas in EMT6
sublines derived in different drugs (the VCR-selected cells
appear larger than the ADM-selected cells) will also influence
the amount of P-glycoprotein measurable per cell.
Western blot analysis was conducted on membrane pro-
teins prepared from both human and mouse resistant cell
lines. When probed with JSB-1, a single major band at a
position corresponding to a Mr of around 160-180 kDa was
seen in membranes prepared only from human resistant cells,
but not from sensitive parent human cells or resistant mouse
cells. By contrast, when probed with 265/F4, a single
170 kDa band was seen in membranes prepared only from
the resistant mouse fibrosarcoma RIF cell lines and no such
band could be seen in membranes prepared from the resistant
EMT6 cells (Figure 2a) or from resistant human cells. With
C219, a 170 kDa band and two additional protein bands of
about 85-95 kDa were evident in membranes prepared from
the resistant cells of both the EMT6 and the RIF cell lines
(Figure 2b) and a single 170 kDa band in membranes from
human resistant cells. However, when mouse resistant cell
membranes were prepared in the presence of the protease
inhibitors, aprotinin, leupeptin and pepstatin, rather than
PMSF alone, only a single 170 kDa protein band was detect-
ed by C219 (Figure 2c). It would appear therefore that the
smaller bands represent degraded fragments of the larger
170 kDa protein.
In order to identify which genes encoding P-glycoprotein
were being expressed in the mouse tumour cell lines, total
RNA was prepared from both resistant and parent cells of
EMT6 and RIF cell lines and following reverse transcription,
cDNA sequences were amplified by the polymerase chain
reaction using primers specific for either mdrla or mdrlb
genes. Resolution of these amplified sequences on 2% aga-
rose is shown in Figure 3. With the mdrlb-specific forward
primer, it was possible to distinguish an amplified DNA
transcript corresponding in size to the expected 289 bp in
material obtained from all the RIF cell lines, but not in that
from the EMT6 cell lines. The band stained only weakly with
ethidium bromide in the parent RIF line and most strongly
in the most resistant RIF 1.0 line. With the mdrla-specific
forward primer, a slightly larger amplified DNA sequence
corresponding to the expected 446 bp was seen in material
taken from all the resistant EMT6 cell lines. The band could
also be distinguished, albeit weakly, in the parent EMT6.
There was progressively increased expression of mdrlb in the
resistant fibrosarcoma lines showing progressively increased
levels of resistance, i.e. RIF/0.1, 0.2, 0.4 and 1.0. However
Table II Immunoreactivity of different monoclonal antibodies with
cytospins prepared from sensitive and resistant human and mouse
tumour cell lines
Blank
Monoclonal antibody (mouse
Cell line C219 MRK16 JSB-J 265/F4 serum)
H69/P - _ _ _ _
H69/LX4 ++ ++ ++ _ _
H69/LX20 ++ ++ ++ - -
H69/VR2 ++ ++ ++ -
EMT6/P - - - - _
EMT6/CRO.2 + - - - -
EMT6/VR1.0 + - - - _
EMT6/ARI.0 ++ - - - _
EMT6/CR2.0 ++ - - - -
RIF-1 - - -
RIF/O.I +/- - - +/- -
RIF/0.2 + - - + _
RIF/0.4 ++ - - ++ _
RIF/l.0 ++ - - ++
Intensity ofstaining: -, negative; +/-, weak; +, strong; + +, very
strong.242 M.A. BARRAND & P.R. TWENTYMAN
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Figure 1 Immunocytochemical staining with C219 (a, b and c) and with 265/F4 (d, e and f) of cytospins prepared from
a EMT6/CRO.2; b, EMT6/VR1.0; c, RIF/0.4; d EMT6/VRI.0; e RIF/0.4 and f, RIF/0.2 (Original magnification x 622).
Table III Absorbance values obtained from whole cell attached
ELISA assays showing the relative amounts ofP-glycoproteins detected
by C219 and by 265/F4 in resistant variants derived from the mouse
mammary tumour cell line, EMT6 and from the mouse fibrosarcoma
cell line, RIF-1
Absorbance at 405 nm per 105 cells
Cell lines with C219 with 265/F4
EMT6/P 0.04 nd
EMT6/CRO.2 0.32 nd
EMT6/AR1.0 0.73 nd
EMT6/VR1.0 1.00 nd
EMT6/CR2.0 1.38 nd
RIF-1 0.02 0.10
RIF/0.1 0.07 0.28
RIF/0.2 0.24 0.40
RIF/0.4 0.42 0.83
RIF/1.0 0.74 1.18
Values shown are the mean ofdata from 2-3 separate experiments.
nd = not determined.
expression of mdrla was evident only in the more resistant
RIF cell lines (Figure 4).
Southern blots were made from some of the gels con-
taining the PCR products and were hybridised with the
mouse-specific pcDR1.3 probe. Following washing to high
stringency, autoradiographs revealed a major radioactive
band corresponding in position to that of the 289bp
sequence amplified with the mdrlb-specific primer. No radio-
active band was evident at the position corresponding to that
of the 446 bp sequence amplified with the mdrla-specific
primer. This was not unexpected since the mdrla sequence
amplified was from a region which shares little homology
a b c
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Figure 2 Immunodetection of P-glycoprotein on Western blots
of membranes prepared from sensitive EMT6/P and RIF-1 and
drug resistant EMT6/ARI.0 and RIF/1.0 cell lines. Filters were
probed with a, 265/F4 or with b and c, C219. Fifty jlg of
membrane protein were loaded per track. Membranes were pre-
pared in the presence of a and b PMSF alone or c a mixture of
aprotinin, leupeptin and pepstatin.
with the transcript of the mdrlb gene and the probe,
pcDRl.3 was derived from a mouse cell line expressing only
the mdrlb gene (Gros et al., 1986a). The amplified sequences
were also oligolabelled and themselves used to probe North-
ern blots of RNA prepared from resistant cells both of the
EMT6 and of the RIF cell lines. The mdrla probe recognised
a band of RNA of size similar to that detected by the
mouse-specific pDRl.3 probe, i.e. around 5 kb. This was
present in all the resistant EMT6 cell lines and also in the
more resistant RIF cell lines. The mdrlb probe recognised a
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Figure 3 Separation of PCR amplified cDNA sequences trans-
cribed from total RNA prepared from EMT6 and RIF-I cell
lines. cDNA in each sample was amplified in the presence of
primers specific either for the mouse mdrla gene a or the mouse
mdrlb gene b. Amplified sequences were resolved on a 2%
agarose gel and visualised by ethidium bromide fluorescence. The
DNA markers are from HaeIII-digested 0X174-RF DNA.
Parent 0.1 0.2 0.4 1.0
__ -_
__ __
a b a b a b a b a b
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RIF-1
Figure 4 Separation of PCR amplified cDNA sequences trans-
cribed from total RNA prepared from RIF-l cell lines with
increasing levels of resistance left to right, sensitive parent RIF-1,
low resistance RIF/0.1 and RIF/0.2, and higher resistance RIF/
0.4 and RIF/l.0. cDNA in each sample was amplified in the
presence of primers specific either for mdrla or mdrlb.
similar sized band of RNA, but this was present only in the
RIF cell lines.
Discussion
MRK16 and JSB-1 stained resistant variants of the human
tumour cell line only and failed to recognise P-glycoprotein
in the mouse MDR cells. Selectivity of MRK16 for the
human mdrl protein has been indicated by previous work
(Thiebaut et al., 1989). C219, which recognises a sequence
present in all P-glycoproteins so far characterised, stained
resistant cells of both human and mouse tumour cell lines.
265/F4 appeared the most selective of the four monoclonal
antibodies, failing to recognise human mdrl P-glycoprotein
on cytospins or Western blots and producing differential
staining between the resistant mouse tumour cell lines. It
seems that this antibody can detect a protein the amount of
which correlates with the level of multidrug resistance in RIF
cell lines, but which is not present in the resistant EMT6
lines. The results of PCR amplification of specific mdr trans-
cripts indicate that in the highly resistant RIF cell lines two
separate genes, mdrla and mdrlb are expressed whilst in the
resistant EMT6 cell lines only one gene, mdrla, is expressed.
It seems highly likely therefore that the basis of the differ-
ential staining with 265/F4 resides in its selective recognition
of the mdrlb gene product.
Whether it is the actual primary amino acid sequence of
the 265/F4 epitope that is lacking in the mdrla protein or
whether the epitope is simply inaccessible to the antibody due
to secondary modifications such as glycosylation or the way
in which the protein is inserted in the membrane of the
EMT6 cells is not entirely clear. The latter suggestion would
however seem unlikely in view of the findings from the
Western blot analysis that 265/F4 retains its ability to bind
to the mdrlb protein that has been solubilised in SDS and
presumably unravelled from its membrane environment.
It is difficult to understand what structural requirements
may be necessary for 265/F4 recognition of different P-
glycoproteins. It has been reported that 265/F4 can produce
positive staining in human lung carcinoma xenografts (Volm
et al., 1988a) and in frozen sections of human renal cell
carcinoma where the distribution of staining paralleled that
produced by C219 (Bak et al., 1990). Yet in our resistant
human small cell lung carcinoma lines which stain strongly
with other anti-P-glycoprotein antibodies, we were unable to
detect any reactivity with 265/F4 either in cytospins or on
Western blots. Similar negative findings have been reported
with 265/F4 on resistant human breast carcinoma (Lathan et
al., 1985). There may be differences between P-glycoproteins
expressed in different human tissues that will influence anti-
body recognition. For instance the disposition of the proteins
within the membrane or post-translational modifications to
the proteins may differ. Certainly the mdrlb P-glycoprotein
expressed in mouse tissues appears to be glycosylated to
different extents in uterine tissue and in MDR cell lines
(Greenberger et al., 1989). Surface modifications might well
be significant for 265/F4 recognition since the antibody,
raised originally against whole intact resistant cells, probably
recognises an external epitope.
Despite the uncertainty surrounding the interpretation of
the antibody recognition of the P-glycoprotein isoforms, it is
clear from the data obtained by PCR that only mdrla is
expressed in the mouse resistant mammary tumour cell lines
whilst both mdrla and mdrlb are expressed in the resistant
fibrosarcoma cell lines and that expression of mdrlb precedes
that ofmdrla during the acquisition of resistance. Expression
of both mdrla and mdrlb within a single cell has been
reported previously in other mouse drug resistant cell lines.
e.g. of the macrophage-like type (Hsu et al., 1989). Here also
the mdrlb gene alone was expressed in the lower resistance
lines and higher resistance was associated with a switch to
mdrla expression. The functional significance of these two
different gene products is not yet clear but it has been
suggested that the mdrla gene product may act as a more
efficient pump to expel drug from the cells. Although both
can confer multidrug resistance in transfection experiments, it
has been shown that there are striking qualitative and quanti-
tative differences in the drug resistance phenotype conveyed
by these two genes (Devault & Gros, 1990). In these partic-
ular experiments, cell clones expressing the mdrlb gene were
more resistant to adriamycin and to colchicine than those
showing an equivalent level of expression of the mdrla gene.
In our cell lines, the mdrla protein appeared more susceptible
than the mdrlb protein to degradation following disruption
of cellular structure, smaller fragments being detectable on
Western blots. However it has been reported that in intact
cells, rates of degradation of these two gene products are
similar (Cohen et al., 1990). The different gene products have
been detected in different amounts in different normal tissuesmdrla AND mdrlb P-GLYCOPROTEINS IN MOUSE MDR CELL LINES 245
in the mouse (Croop et al., 1989), very high levels of the
mdrlb gene product being found in the uterus of the preg-
nant mouse where it may play an important role during
gestation (Arceci et al., 1988; Greenberg et al., 1989). The
possibility is that they may therefore be involved with the
transport of quite different endogenous substances. It is
thought that each of these mdr genes is regulated in a tissue-
specific manner. An understanding of the factors involved in
this differential regulation may well therefore be important in
designing cancer chemotherapy strategies (Croop et al.,
1989).
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